Clovis Oncology Outlines Clinical Program for PARP Inhibitor Rucaparib Using Foundation's NGS Test | GenomeWeb

Originally published Nov. 18.

Clovis Oncology has designed a clinical trial program for its PARP inhibitor rucaparib, through which the company hopes to define a DNA repair gene signature associated with drug response, use that signature to garner US Food and Drug Administration approval for the drug in a molecularly defined patient subset, and launch the first next-generation sequencing-based companion test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.